Lead Sponsor

Bristol-Myers Squibb

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Meet ARA criteria for diagnosis of RA with active disease.
•RA diagnosis for at least 1 year.
•\> = 6 swollen joints.
•\> = 8 tender joints.
•Taking methotrexate (MTX) or MTX plus not more than 1 added oral DMARD for \> = 3 months and stable for 28 days prior to dosing.

•Serious acute or bacterial infection in last 3 months.
•Chronic or recurrent bacterial infections.
•History of TB within previous 3 years or old TB not adequately treated.
•Specific lab test abnormalities
•History of cancer within 5 years.
•Exposure to CTLA4Ig (Cytotoxic T-lymphocyte (T-cell)-associated antigen 4Ig), belatacept, rituximab, efalizumab, alefacept, or other investigational drug or biologic.
•Treatment with hydroxychloroquine, azathioprine, leflunomide, immunoadsorption columns, mycophenolate mofetil, cyclosporine, D-Penicillamine or calcineurin inhibitors.
•Exposure to live vaccines.

Related studies

NCT07171983 · Rheumatoid Arthritis

NCT05869955 · Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, and more

NCT07558850 · Rheumatoid Arthritis, Dermatomyositis, and more

NCT07536529 · Inflammatory Joint Diseases, Rheumatoid Arthritis (RA), and more

NCT06329401 · Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, and more

Study to Assess Steady-State Trough Concentrations, Safety, and Immunogenicity of Abatacept After Subcutaneous (SC) Administration to Subjects With Rheumatoid Arthritis (RA)